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Abstract
The sequence of Mycobacterium tuberculosis, completed in 1998, facilitated both the development of genomic tools,
and the creation of a number of mycobacterial mutants. These mutants have a wide range of phenotypes, from atten-
uated to hypervirulent strains. These phenotypes must be confirmed, to rule out possible secondary mutations that
may arise during the generation of mutant strains. This may occur during the amplification of target genes or during
the generation of the mutation, thus constructing a complementation strain, which expresses the wild-type copy of
the gene in the mutant strain, becomes necessary. In this study we have introduced a two-step strategy to construct
complementation strains using the Ag85 promoter. We have constitutively expressed dosR and have shown dosR
expression is restored to wild-type level.
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The completion of the entire sequence of Mycobacte-
rium tuberculosis (Cole et al., 1998) launched a new era in
tuberculosis research. In order to study the function of M.
tuberculosis genes, several mutants have been produced by
homologous recombination and studied in animal models
(Parish and Stoker 2000; Movahedzadeh et al., 2004, 2008,
2010). There is a wide range of phenotypes, from highly at-
tenuated mutants (Smith et al., 2001; Movahedzadeh et al.,
2004) to hypervirulent strains (McAdam et al., 2002; Par-
ish et al., 2003). These phenotypes require confirmation by
the generation of complementation strains, whereby the
wild-type copy of the gene is re-introduced into the mutant
strain. By complementation of the mutant strain, one can
ensure that the observed mutant phenotype, e.g. increased
virulence of M. tuberculosis with the loss of dosR, is actu-
ally due to the loss of dosR and not to secondary mutations
that may have arisen during the creation of the mutant
strain.
Several cloning systems for mycobacteria have been
developed, based on M. fortuitum plasmid pAL5000 (La-
bidi et al., 1985); such plasmids are generally called shuttle
plasmids.Althoughthesehavealowcopynumberinmyco-
bacteria, where replication is driven by the mycobacterial
Ori, they have high copy number in E. coli. For successful
complementation, the wild-type gene must be stably ex-
pressed in the mutant strain. This may be accomplished by
using a replicating plasmid that contains the mycobacterial
Ori, or by an integrating plasmid into the genome of myco-
bacteria. A competition experiment with M. bovis BCG us-
ing pMV261 and pMV361 vectors (Stover et al., 1991),
showed that only pMV361 was stably maintained. These
two plasmids both have an E. coli origin of replication, a
kanamycin (Km) resistance gene and the hsp60 promoter.
The difference is that pMV261 is a replicative vector con-
taining the pAL5000 origin of replication and pMV361 is
an integrative vector containing an attachment site and the
origin of replication genes from mycobacteriophage L5.
The use of integrative plasmids for complementation
proved to be more advantageous (Stover et al., 1991; Ku-
mar et al., 1998), and they have been successfully devel-
oped for mycobacteria, using attP and int gene of the tem-
perate mycobacteriophage L5, such as pMV306
(MedImmune,MD)andpUC-Int(Mahenthiralingametal.,
1998). One reported disadvantage of the L5 integration
vector is that the integration locus would be unfavourable
for transcription of integrated genes, when using native
promoters (Murry et al., 2005). This is even more marked,
when the gene being expressed under its native promoter is
not the first gene in the operon. The Ag85 promoter has
been used in our laboratory and many others (Abdallah et
al., 2006; Hu et al., 2006). The 85A antigen is part of a se-
creted antigenic complex, and represents one of the major
secreted proteins from slowly growing mycobacteria (Wi-
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Short CommunicationkerandHarboe,1992).Thepromoterregioncontrollingthe
expression of this antigen has already been analyzed
(Kremer et al., 1995). In this study, a two-step strategy for
constructing complementation strains using the Ag85 pro-
moter was introduced. We have used this vector to express
dosR constitutively in Tame 16 (dosR mutant) and have
shown restoration of dosR expression to wild-type levels.
Deletion of dosR (Rv3133c), a transcription factor that me-
diates the hypoxic response of M. tuberculosis (Park et al.,
2003), resulted in increased virulence in M. tuberculosis
(Parish et al., 2003). dosR is part of an operon encoding
three genes: Rv3134c (dosT), Rv3133c (dosR), and
Rv3132c (dosS).
pEM37 (donated by E. Machowski) was digested
with BglII-BamHI and the 275 bp fragment, containing the
Ag85 promoter, was then isolated and cloned into the
BamHI site of p2Nil (Parish and Stoker, 2000). This plas-
mid containing the Ag85 promoter consists of a multiple
cloning site (MCS) and a kanamycin resistance gene with
an origin of replication from E. coli.
To permit in-frame cloning into pFM209 under the
Ag85 promoter, the following steps is advised: In the first
step, the coding sequence of the gene, plus one extra base
pair of the upstream sequence should be amplified (high fi-
delity PCR kit, Boehringer Mannheim), using primers to
introduce BamHI restriction sites for both N and C termini,
followed by digestion with BamHI (if a BamHI site exits
within the gene, BglII can be used), and final cloning into
the BamHI site of pFM209. In the second step, the 3 kb
HindIIIfragmentofpUC-Gm-int(Mahenthiralingametal.,
1998), containing the attP site, Gm cassette and L5 in-
tegrase gene should be cloned into the HindIII site of
pFM209, in order to produce the integrated version. If a
HindIII site exists within the gene of interest, a PvuII cas-
sette of pUC-Gm-int can be cloned into the PmlI site of
pFM209. Cloning the HindIII cassette of pUC-Gm-int,
prior to that of the gene of interest, is inadvisable since this
cassette has a BamHI restriction site. However, having the
gentamycin marker in this cassette facilitates screening of
the correct clone in the second stage. This is summarized in
Figure 1.
In this study, dosR was constitutively expressed by
usingthisvector.dosRwasamplifiedwiththeExpandHigh
Fidelity PCR system using M. tuberculosis H37Rv
genomic DNA as template and DMSO at 5%. The primers
used (each at 300 nM) were dosR-Bam1 (CGCGGATCC
GGTGGTAAAGGTC) and dosR-Bam2 (CGAGGATCC
TCATGGTCCATCA). The temperature cycle used was as
follows:aninitial3minat94°CtodenaturetheDNA;then
10cyclesof45sat94°C,1minat63°Cand1minat72°C;
then 25 cycles of 45 s at 94 °C, 1 min at 63 °C and 1 min
plus 20 s per cycle at 72 °C; and finally an extension step of
72 °C for 7 min. The resulting PCR product was digested
with BamHI and cloned into the BamHI site of pFM209.
The resulting clones were subjected to restriction digestion
using several enzymes, and were run on a gel to select for
the correct orientation of the gene, thereby producing
pFM210.TheHindIIIcassetteofpUC-Gm-int,carryingthe
int and gm genes, was cloned into the HindIII site of
pFM210 to produce pFM211. The final plasmid was se-
quenced to confirm that no mutations had been introduced,
during either dosR amplification, or pFM211construction.
TheplasmidsusedinthisstudyaresummarizedinTable1.
RTq-PCR experiments were carried out to determine
thelevelofdosRmRNAexpressioninexponentialcultures
of H37Rv and a dosR mutant with constitutive expression
of dosR under the Ag85 promoter. Expression levels were
normalizedtothoseofsigAmRNAandcalculatedbasedon
the RNA used for reverse transcription. RNA was prepared
from an exponential (7-day) rolling culture of M. tubercu-
losis H37Rv (Betts et al., 2002) and cDNA synthesis was
carried out using Superscript II (Invitrogen), according to
the manufacturer's protocol. Reverse-transcription quanti-
tative PCR (RTq-PCR) reactions were set up using the Dy-
NAmo SYBR Green qPCR kit (MJ Research), and per-
formed using the DNA Engine Opticon 2 System (Genetic
Research Instrumentation). Reactions containing 1X DNA
Master SYBR Green I mix, 1 L cDNA product and
0.3 mM of each primer in 20 L, were set up on ice. Sam-
ples were heated to 95 °C for 10 min before cycling for
35 cycles of 95 °C for 30 s, 60 °C (dosR), or 62 °C (sigA)
for 20 s, and 72 °C for 20 s. Fluorescence was captured at
the end of each cycle, after heating to 80 °C to ensure the
denaturation of primer dimers. The experiment was re-
peatedtwiceusingcDNAfromeachofthetwoindependent
RNA preparations. We showed that when dosR is constitu-
tively expressed in the mid-exponential phase in Fame101
(dosR::pFM211), the level of dosR mRNA is 0.54 (95%
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Figure 1 - Construction of pFM209 and the two-step strategy for comple-
mentation.confidence interval 0.38-0.75) to that of sigA. A t-test was
run and no significant difference was observed between the
constitutivelyexpresseddosRinthedosRmutantandinthe
wild-type. In H37Rv the level of dosR mRNA is 0.55 (95%
confidenceinterval0.47-0.65)tothatofsigA(Figure2).As
expected, no dosR expression was observed under the
above conditions (not detectable, below 50,000 copy). We
have also used this method to complement one of the un-
known M. tuberculosis genes, located in the middle of an
operon. Complementation of this mutant restored the atten-
uation phenotype observed in a mouse model (unpublished
data).
The method described here is useful for the com-
plementation of mycobacterial mutants, especially for ge-
nes located in the middle of an operon, where it would be
difficult to use its own promoter. Furthermore, by using the
integrative approach, the instability previously reported in
certain shuttle vectors (Stover et al., 1991; Kumar et al.,
1998),wouldbeavoided.Althoughthehsp60promoterhas
been used successfully for gene expression in mycobacte-
ria, some problems have been reported (Nicola Casali, PhD
thesis, 1998) when expressing lacZ under this promoter,
such as colonies rapidly losing color. When the plasmids
were extracted, some rearrangements or deletions were
found. Possibly, there are two potentially related but sepa-
rate problems: the expression being too high (causing tox-
icity problems to the cells), and the tendency of the
promoter DNA to rearrange. We favour the use of Ag85
promoter since it has been shown by others to be more sta-
ble than the Hsp60 promoter (Haeseleer, 1994; Al-Zarouni
and Dale, 2002).
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